Celyad Oncology S.A (CYAD) | Stock Overview & Key Data
Celyad Oncology S.A Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €70.95 on May 18, 2015
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Financial Highlights
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Celyad Oncology S.A
CYAD
|
14.10M Small-cap | -7.14% | -10.34% | -21.21% | 44.44% | 44.44% | -35.00% | -50.94% | -94.34% | -99.36% | -98.71% | -98.71% |
|
UCB S.A
UCB
|
50.14B Large-cap | -0.69% | 9.37% | 1.69% | 8.86% | 10.67% | 68.19% | 220.47% | 222.73% | 332.23% | 618.13% | 618.13% |
|
Argenx SE
ARGX
|
41.43B Large-cap | -0.26% | 9.81% | 24.18% | 24.18% | 24.18% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% | 29.01% |
|
European Medical
ALEMS
|
20.74M Small-cap | 1.63% | 2.04% | 1.01% | -7.41% | 6.84% | 6.38% | -16.39% | -95.91% | -99.74% | -99.78% | -99.78% |
|
Biosenic SA
BIOS
|
1.57M Small-cap | N/A | N/A | N/A | N/A | N/A | -80.00% | -98.25% | -99.73% | -99.94% | -98.97% | -98.97% |
| N/A | -1.22% | 14.47% | 5.09% | 6.07% | 7.58% | 85.71% | 225.88% | 200.37% | 364.29% | 681.77% | 681.77% |
Ownership & Short Interest
Calculate Your Celyad Oncology S.A Investment Returns
Long-Term Investment Performance Analysis
Celyad Oncology S.A stock price in Jul 2016 was €22.01, A €1,000.00 lump sum investment in Celyad Oncology S.A made 9 years ago would be worth approximately €11.81 today, representing a negative return of -98.82%. This translates to an annualized return (CAGR) of -36.11%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is CYAD's 52-week high and low?
- In the last 52 weeks, Celyad Oncology S.A reached a high of €0.65 (on February 17, 2026) and a low of €0.16 (on December 30, 2025).
- What is the market cap and P/E ratio for CYAD?
- Curious about Celyad Oncology S.A's size and valuation? Its market capitalization stands at 14.10M. When it comes to valuation, the P/E ratio (trailing twelve months) is 15.75, and the forward P/E (looking ahead) is 0.49.
- Does CYAD pay dividends? If so, what's the yield?
- As for dividends, Celyad Oncology S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Celyad Oncology S.A's main competitors or similar companies to consider before investing?
When looking at Celyad Oncology S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return UCB S.A
UCB50.14B Healthcare Biotechnology 68.19% 220.47% Argenx SE
ARGX41.43B Healthcare Biotechnology 29.01% 29.01% European Medical
ALEMS20.74M Healthcare Biotechnology 6.38% -16.39% Biosenic SA
BIOS1.57M Healthcare Biotechnology -80.00% -98.25% Financière de Tubize
TUBN/A Healthcare Biotechnology 85.71% 225.88% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Celyad Oncology S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Celyad Oncology S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 56.33%, the Debt to Equity ratio from the most recent quarter is 0.00, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for CYAD?
- Looking at Celyad Oncology S.A's growth, its revenue over the trailing twelve months (TTM) was €21K. Compared to the same quarter last year (YoY), quarterly revenue grew by -95.90%, and quarterly earnings saw a YoY growth of N/A.
- How much of CYAD stock is held by insiders and institutions?
- Wondering who owns Celyad Oncology S.A stock? Company insiders (like executives and directors) hold about 10.78% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 58.59%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.